NPPA fixes retail price of 7 drug formulations

NPPA fixes retail price of 7 drug formulations through a recent notification dated 31-12-2019 in exercise of the powers conferred by under the DPCO 2013

808
NPPA National Pharmaceutical Pricing Authority
Picture: Pixabay

Last Updated on January 5, 2024 by The Health Master

New Delhi: NPPA fixes retail price of 7 drug formulations, through a recent notification.

The apex drug price regulatory agency, the National Pharmaceutical Pricing Authority (NPPA) fixes retail price of 7 drug formulations in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013. 

For notification, Click here

The retail price of 7 drug formulations fixation are exclusive of goods and services tax (GST).

NPPA fixes retail price of 7 drug formulations include combination drug are as under:

Clarithromycin + Esomeprazole + Amoxicillin Tablet;

Bictegravir + Emtricitabine + Tenofovir Tablet,

Ranitidine Hydrochloride + Dicyclomine Hydrochloride + Simethicone Tablet;

Darunavir + Ritonavir Tablet;

Cefotaxime Sodium Injection;

Clobazam Tablet 7.5 mg

Clobazam Tablet 2.5 mg

Various drugmakers including the following are involved in manufacturing the said drug formulations under different brand names:

Sun Pharmaceuticals Ltd.,
Alkem Lab, Aurobindo Pharma,
Emcure Pharma,
Hetero Lab,
Mankind Pharma,
Windlas Biotech
Malik Lifesciences

The formulations mentioned in the list include antibiotics, indicated to treat a variety of bacterial infections; an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying; seizures drug and others.

Also read another news of NPPA, Click the links below
NPPA fixes price of 2 inhaler devices
NPPA fixes retail prices of 75 formulations under DPCO 2013
NPPA fixes retail prices of 12 formulations
NPPA fixes retail prices of 21 formulations